Data in Brief of: Clinical benefits of moxifloxacin as initial treatment of community-acquired pneumonia: Data from meta-analyses

Moxifloxacin and levofloxacin are currently recommended as empirical initial treatment options for community-acquired pneumonia (CAP) in China by clinical guidelines and widely used in clinical settings. Several clinical outcomes comparing the efficacy and safety profiles of moxifloxacin versus levo...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xiwen, Han, Yi, Jian, Yifei, Chen, Liping, Xuan, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455983/
https://www.ncbi.nlm.nih.gov/pubmed/34584913
http://dx.doi.org/10.1016/j.dib.2021.107352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455983/
https://www.ncbi.nlm.nih.gov/pubmed/34584913
http://dx.doi.org/10.1016/j.dib.2021.107352

Ejemplares similares